Jasper Therapeutics Announces Completion Of 18-Patient Enrollment In Phase 2 IgA Nephropathy Cohort Of Vensobafusp Alfa; Initial Data Expected By Year-End

Loading news article.

Jasper Therapeutics Announces Completion Of 18-Patient Enrollment In Phase 2 IgA Nephropathy Cohort Of Vensobafusp Alfa; Initial Data Expected By Year-End | WAPE

Jasper Therapeutics Announces Completion Of 18-Patient Enrollment In Phase 2 IgA Nephropathy Cohort Of Vensobafusp Alfa; Initial Data Expected By Year-End

Article summary

Related companies

Analyzed by WAPE AI.

Comments —